Trends of skin cancer mortality after transplantation in the United States: 1987 to 2013 - 21/06/16
Abstract |
Background |
Solid organ transplant recipients are at increased risk of skin cancer, but population-based mortality data are limited.
Objective |
Mortality and predictors of skin cancer death posttransplantation were investigated.
Methods |
All US organ transplant recipients between 1987 and 2013, identified through the Organ Procurement and Transplantation Network Standard Transplant Analysis and Research file, were included. Mortality and hazard ratios (HR) were calculated for the overall population and patient subgroups.
Results |
The overall mortality was 5308 per 100,000 person-years and the skin cancer–specific mortality was 35.27 per 100,000 person-years. Risk factors associated with skin cancer death included thoracic versus abdominal transplantation (HR 2.90, 95% confidence interval [CI] 2.52-3.34), age over 50 years (HR 2.86, CI 2.43-3.38), white race (HR 6.29, CI 4.63-8.53), and male sex (HR 1.85, CI 1.57-2.19). Mortality was highest for malignant melanoma (mortality of 11.48), followed by squamous cell carcinoma (mortality of 4.94) and Merkel cell carcinoma (mortality of 4.59).
Limitations |
Limitations of this study included potential underreporting and misclassification of death from skin cancer in the data set.
Conclusion |
Mortality from posttransplantation skin cancer is reported. Older patients, male patients, white patients, and thoracic transplant recipients had increased mortality from skin cancer.
Le texte complet de cet article est disponible en PDF.Key words : cause of death, cutaneous carcinoma, iatrogenic immunosuppression, mortality outcomes, nonmelanoma skin cancer, organ transplant recipients, rate, solid organ transplantation
Abbreviations used : CI, HR, MCC, MM, NMSC, OTR, SCC, STAR
Plan
| Dr Garrett and Mr Lowenstein contributed equally to this work as joint first authors. |
|
| Funding sources: Drs Arron and Garrett are funded by the American Academy of Dermatology Transplant Skin Cancer Network. Dr Garrett was funded by an unrestricted fellowship award from Galderma. |
|
| Conflicts of interest: None declared. |
Vol 75 - N° 1
P. 106-112 - juillet 2016 Retour au numéro
Article précédent
- Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis
- Robert Bissonnette, David M. Pariser, Norman R. Wasel, Joana Goncalves, Robert M. Day, Rongdean Chen, Michael Sebastian
- The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
- Reinhard Dummer, Alexander Guminski, Ralf Gutzmer, Luc Dirix, Karl D. Lewis, Patrick Combemale, Robert M. Herd, Martin Kaatz, Carmen Loquai, Alexander J. Stratigos, Hans-Joachim Schulze, Ruth Plummer, Sven Gogov, Celine Pallaud, Tingting Yi, Manisha Mone, Anne Lynn S. Chang, Frank Cornélis, Ragini Kudchadkar, Uwe Trefzer, John T. Lear, Dalila Sellami, Michael R. Migden
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?